Madrigal Pharmaceuticals (NASDAQ: MDGL)
$449.14
(-2.1%)
-$9.52
Price as of October 1, 2025, 4:00 p.m. ET
Madrigal Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Madrigal Pharmaceuticals Company Info
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
News & Analysis
The Fool has written over 100 articles on Madrigal Pharmaceuticals.
Featured Article
Biotech vs. Pharma: What's the Difference?
Keith Speights | Sep 29, 2025
Featured Article
Madrigal (MDGL) Q2 Revenue Soars 1,313%
Motley Fool Markets Team | Aug 5, 2025
Why Madrigal Pharmaceuticals Stock Is Soaring Today
Keith Speights | Feb 26, 2025
Why Madrigal Pharmaceuticals Stock Was Plummeting This Week
Eric Volkman | Jan 17, 2025
Why Madrigal Pharmaceuticals Stock Is Sinking Today
Keith Speights | Jan 13, 2025
3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move
Alex Carchidi | Nov 23, 2024
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More
Alex Carchidi | Nov 10, 2024
There's a bright future ahead for this company.
Is Madrigal Pharmaceuticals Stock a Buy?
Prosper Junior Bakiny | Aug 17, 2024
The biotech could be worth a lot more in 10 years.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.